论文部分内容阅读
目的：研究冠心病（CHD）患者冠脉循环中血浆线粒体偶联因子-6（MCF-6）含量与冠脉狭窄程度的相关性。方法：选择冠心病患者64例（冠心病组），根据冠脉病变程度分为单支、双支、多支病变组；另选冠脉正常者20例作为正常对照组，用放免方法分别测定各组外周、冠状窦、冠状窦与主动脉根部血浆 MCF-6浓度，并用多元线性逐步回归分析分析冠脉循环血浆MCF-6含量与冠脉狭窄程度的相关性。结果：冠心病患者外周、主动脉根部、冠状窦血浆MCF-6浓度较正常对照组均显著升高（P＜0.05）；冠心病组冠状窦血浆 MCF-6浓度较主动脉根部及外周血的均显著升高[（402±56）pg/ml比（348±48）pg/ml比（340±51）pg/ml，P＜0.01]；多支病变组的血浆MCF-6浓度较单支、双支病变组的显著升高（P＜0.05～0.01）；多元线性逐步回归分析显示冠状窦及主动脉根部血浆MCF-6浓度与 Gensini积分均呈明显正相关（r＝0.650，P＜0.01；r＝0.711，P＜0.01）。结论：线粒体偶联因子-6参与了冠心病的病理生理过程，在冠心病的发病过程中可能是一种较为重要的血管活性物质。“,”Objective:To study correlation betWeen plasma mitochondrial coupling factor-6 (MCF-6)level in coro-nary circulation and coronary stenotic degree in CHD patients.Methods:A total of 64 CHD patients Were selected as CHD group,and they Were further divided into single-vessel group,double-vessel group and multi-vessel coronary disease group;another 20 cases With normal coronary artery Were enrolled as normal control group.Radioimmuno-assay method Was used to measure plasma MCF-6 concentration in peripheral,coronary sinus and aortic root in each group.Multivariant linear gradual regressive analysis Was used to analyze above-mentioned correlation.Results:Compared With normal control group,there Was significant increase in plasma MCF-6 concentration in peripheral, aortic root and coronary sinus in CHD patients (P<0.05 all);compared With aortic root and peripheral plasma, there Was significant increase in MCF-6 concentration [(348±48)pg/ml vs.(340±51)pg/ml vs.(402±56)pg/ml, P<0.0 1 all]in coronary sinus of CHD group;Compared With single-vessel group,double-vessel group,there Were increase in MCF-6 concentration in multi-vessel coronary disease group (P<0.05~<0.01);Multivariant linear gradual regressive analysis indicated that Gensini score Was significant positively correlated With plasma MCF-6 con-centrations in coronary sinus and aortic root (r=0.650,P<0.01;r=0.711,P<0.01).Conclusion:Mitochondrial coupling factor-6 participates in the pathophysiological process of coronary heart disease,Which may be an impor-tant vasoactive substance during development of coronary heart disease.